If journalists would like to ask actual substantive questions for a change at the GOP debate in Milwaukee, they could start by asking about the biggest threat to our nation’s future security–the burgeoning entitlement monster. Fox Business is the ideal sponsor for such a debate. There are huge business and economic implications of the unrestrained growth of Medicare, Medicaid, and Social … [Read more...] about How About A Debate Over America’s Future Prosperity?
Lift The Ban On Physician-Owned Hospitals
As Congress considers year-end legislative options, one small change in the Affordable Care Act could make a big difference in access to quality health care for millions of Americans: Lifting the ban on creation and expansion of physician-owned hospitals. Physicians have an ownership stake in approximately 250 hospitals operating in 34 states, and they have a strong track record of providing … [Read more...] about Lift The Ban On Physician-Owned Hospitals
400,000 Citizens To Lose Health Insurance (Again) Because Of Obamacare Co-Op Failures
The two largest state health insurance co-operatives created as part of a grand ObamaCare experiment have announced they are closing at the end of this year, joining others that have failed and even more that are insolvent and likely to fail. The Kentucky Health Cooperative announced on Friday it is going out of business and will not enroll new members next year, leaving 51,000 members to find … [Read more...] about 400,000 Citizens To Lose Health Insurance (Again) Because Of Obamacare Co-Op Failures
CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market
The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry. The Centers for Medicare and Medicaid Services (CMS) has proposed a rule that would guide how Medicare pays for a new class of medicines used in physicians’ … [Read more...] about CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market
Clinton drug plan would backfire on patients
Democratic presidential candidate Hillary Clinton has piled bad new ideas on top of bad old ideas with her plan to try to lower prescription drug prices in America. Her proposals to rein in prescription drug costs involve forcing pharmaceutical companies to meet a government quota for investing in research, denying companies tax breaks for consumer advertising, and capping out-of-pocket … [Read more...] about Clinton drug plan would backfire on patients
A Bad-Actor, Not A Pharmaceutical Innovator, Causes Outrage Over Drug Prices
A profiteer masquerading as a pharmaceutical company executive has set the Internet afire with his 5,000% price increase for a rare but important drug used by AIDS and some cancer patients. Martin Shkreli, a 32-year-old former hedge fund manager, cornered the market on Daraprim, a drug used to treat a life-threatening parasitic infection. His start-up company, Turing Pharmaceuticals, bought … [Read more...] about A Bad-Actor, Not A Pharmaceutical Innovator, Causes Outrage Over Drug Prices
70 Changes to ObamaCare…So Far
70 changes so far to ObamaCare(PDF) By our count at the Galen Institute, more than 70 significant changes have been made to the Patient Protection and Affordable Care Act, at least 43 that the Obama administration has made unilaterally, 24 that Congress has passed and the president has signed, and three by the Supreme Court. Changes By Administrative Action 1.) Employee reporting: The IRS … [Read more...] about 70 Changes to ObamaCare…So Far
First Biosimilar Medicine Launches; Price Disappoints Those Hoping For Deeper Discount
Pharmaceutical prices are dominating public concerns about health care, according to a recent poll by the Kaiser Family Foundation that shows three-quarters of Americans support limiting how much drug companies can charge for high-cost drugs. So it’s especially disappointing to see that the first imitators of a new generation of biologic cancer drugs approved for the U.S. market will be started … [Read more...] about First Biosimilar Medicine Launches; Price Disappoints Those Hoping For Deeper Discount